慢性阻塞性肺病（COPD）：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 西班牙市場（輕度至中度細分市場）預計將從約 2.19 億美元成長到約 2.31 億美元（年複合成長率約 0.5%）。
• 受非專利吸入療法和疾病流行率穩定的推動，以及突破性創新有限，成長仍然緩慢。

對慢性阻塞性肺病（COPD）新型治療方法和治療策略的深入了解

Thelansis 發布的「慢性阻塞性肺病(COPD) 新型治療方法、未滿足的需求和目標產品概況 (TPP) 洞察報告 - 2026」全面分析了該適應症的關鍵新型治療方法和主要藥物開發機會，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

慢性阻塞性肺病（COPD）概述

慢性阻塞性肺病（COPD）是全球慢性疾病和死亡的主要原因之一，目前也是全球主要死因之一。此疾病的特徵是由於慢性發炎、氣道重塑和肺實質進行性破壞而導致的持續性氣流受限。

病理學，慢性阻塞性肺病（COPD）涉及氣道狹窄、肺泡附著喪失和肺彈性下降，從而阻礙氣流，尤其是在呼氣時。這會導致氣體滯留、氣體交換減少和進行性呼吸功能障礙。

診斷可透過肺功能測定來確認，支氣管擴張劑給藥後FEV1/FVC比值小於0.70提示氣流阻塞。然而，疾病的嚴重程度並非僅取決於氣流受限；症狀的嚴重程度（例如呼吸困難、咳嗽）和病情加重的頻率在臨床評估中也起著重要作用。

現代慢性阻塞性肺病（COPD）管理採用多方面方法，結合肺功能測定分級、症狀嚴重程度和急性惡化風險來確定治療策略。治療包括支氣管擴張劑（長效BETA2受體激動劑/長效抗膽鹼能藥物）、吸入性糖皮質激素（ICS）和症狀治療，旨在緩解症狀、預防急性惡化並提高生活品質。

主要亮點

• 慢性阻塞性肺病是一種慢性呼吸系統疾病，盛行率高，在全球造成嚴重的死亡負擔。
• 預計美國受影響的人數將從約 2,810 萬增加到約 3,300 萬（年複合成長率約 1.6%）。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 大公司
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 估算主要未滿足需求的市場規模
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• SMSbiotech
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech, Inc.
• Verona Pharma plc
• Keymed Biosciences Co.Ltd
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Eurofarma Laboratorios SA
• AstraZeneca
• Sunshine Guojian Pharmaceutical（Shanghai）Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• Regend Therapeutics
• Nuance Pharma（shanghai）Co., Ltd
• Upstream Bio Inc.
• Bambusa Therapeutics
• Areteia Therapeutics
• Chia Tai Tianqing Pharmaceutical（Guangzhou）Co., Ltd.
• Anhui Hemay Pharmaceutical Co., Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Mabwell（Shanghai）Bioscience Co., Ltd.
• S-INFINITY Pharmaceuticals Co., Ltd
• Merck Sharp &Dohme LLC
• Mesoblast, Inc.
• Joincare Pharmaceutical Group Industry Co., Ltd
• Ganzhou Hemay Pharmaceutical Co., Ltd
• Chiesi Farmaceutici SpA
• Bun Yao Biotechnology Co., Ltd
• Generate Biomedicines
• Rise Therapeutics LLC
• AeroRx Therapeutics Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Chronic Obstructive Pulmonary Disease (COPD) Emerging Therapy and TPP Insights

Thelansis's "Chronic Obstructive Pulmonary Disease (COPD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a major global cause of chronic morbidity and mortality, currently ranking among the leading causes of death worldwide. The disease is characterized by persistent airflow limitation resulting from chronic inflammation, airway remodeling, and progressive destruction of lung parenchyma.

Pathophysiologically, COPD involves narrowing of small airways, loss of alveolar attachments, and reduced lung elasticity, which impair airflow, particularly during exhalation. This leads to air trapping, reduced gas exchange, and progressive respiratory dysfunction.

Diagnosis is confirmed using spirometry, with a post-bronchodilator FEV1/FVC ratio <0.70 indicating airflow obstruction. However, disease burden is not solely determined by airflow limitation; symptom severity (e.g., dyspnea, cough) and frequency of exacerbations play a critical role in clinical assessment.

Modern COPD management follows a multidimensional approach, combining spirometric classification with symptom burden and exacerbation risk to guide therapy. Treatment includes bronchodilators (LABA/LAMA), inhaled corticosteroids (ICS), and supportive care, aimed at reducing symptoms, preventing exacerbations, and improving quality of life.

Key Highlights

• COPD is a high-prevalence, chronic respiratory disease with significant global mortality burden
• US prevalent population expected to grow from ~28.1M to ~33.0M (~1.6% CAGR)

Market Overview

• Spain (mild-to-moderate segment) market projected to grow from ~$219M to ~$231M (~0.5% CAGR)
• Growth remains modest, driven by generic inhalation therapies and stable disease prevalence, with limited breakthrough innovation

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• SMSbiotech
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech, Inc.
• Verona Pharma plc
• Keymed Biosciences Co.Ltd
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Eurofarma Laboratorios S.A.
• AstraZeneca
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• Regend Therapeutics
• Nuance Pharma (shanghai) Co., Ltd
• Upstream Bio Inc.
• Bambusa Therapeutics
• Areteia Therapeutics
• Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
• Anhui Hemay Pharmaceutical Co., Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Mabwell (Shanghai) Bioscience Co., Ltd.
• S-INFINITY Pharmaceuticals Co., Ltd
• Merck Sharp & Dohme LLC
• Mesoblast, Inc.
• Joincare Pharmaceutical Group Industry Co., Ltd
• Ganzhou Hemay Pharmaceutical Co., Ltd
• Chiesi Farmaceutici S.p.A.
• Bun Yao Biotechnology Co., Ltd
• Generate Biomedicines
• Rise Therapeutics LLC
• AeroRx Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)